Longer Dosing Interval of Zoledronic Acid Found Acceptable f
Patients with bone metastasis due to multiple myeloma, breast or prostate cancer, who received zoledronic acid every 12 weeks for two years, did not have increased risk of skeletal-related events compared to patients who received the drug every four weeks, researchers have found.

The study, “Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases,” published in JAMA, suggests that using the treatment every 12 weeks might be an acceptable option for these patients.